PXD101

What PXD101 Means in Everyday Medical Language

PXD101 is another name for the drug belinostat, which is also sold under the brand name Beleodaq. This medicine is used mainly to treat adults with peripheral T-cell lymphoma, a rare type of blood cancer that affects certain white blood cells important for the immune system. Belinostat works by blocking enzymes that cancer cells need to grow and divide. By interfering with these enzymes, it can slow down or stop cancer cells from multiplying and may even cause them to die. It may also prevent tumors from developing new blood vessels, which tumors need to grow larger.

Why Belinostat Can Matter in Cancer Care

Peripheral T-cell lymphoma can be difficult to treat, especially if it returns after initial therapies or does not respond well to them. Belinostat offers an option for patients in these situations. It belongs to a group of drugs called histone deacetylase inhibitors, which work differently from many traditional chemotherapy drugs. This unique action may help control the cancer when other treatments have not worked. Belinostat may also make cancer cells more sensitive to other cancer drugs, potentially improving the effectiveness of combined treatments.

What Patients Might See or Hear About Belinostat

Patients might hear the names Beleodaq, belinostat, or PXD101 during discussions about treatment options, especially if previous treatments have not been successful. The drug is usually given through an intravenous (IV) infusion. Patients may receive information sheets or hear about possible side effects and how the drug fits into their overall care. Because belinostat was approved under an accelerated program, doctors may explain that ongoing studies are still confirming its full benefits and safety.

Where the Term Might Appear

The term belinostat or Beleodaq may appear in treatment plans, medical reports, drug information sheets, or clinical trial listings. It is specifically approved for peripheral T-cell lymphoma that has returned or not improved with other treatments. Patients might also see related terms like PXD101, which is another name for the same drug. It may also come up during discussions about clinical trials or new treatment options.

What Belinostat Does Not Automatically Mean

Hearing about belinostat does not mean it is the best or only treatment option for every patient with lymphoma or cancer. It is not a cure for all cancers and is approved only for certain cases of peripheral T-cell lymphoma. Its use depends on many factors, including the type of cancer, previous treatments, and overall health. Patients should not assume that belinostat will be used or that it guarantees a specific outcome.

Common Questions to Ask Your Care Team

Patients and caregivers may find it helpful to ask questions such as: How does belinostat work in my specific case? What side effects should I expect? How will the drug be given? Are there other treatments that work well with belinostat? How does this drug fit into my overall treatment plan? Understanding these points can help patients feel more informed and involved in their care.

How to Use This Information Safely

This information is meant to help you understand what belinostat (Beleodaq, PXD101) is and how it might be used. It does not decide what is safe or right for any individual patient. If you see this term in your medical records or hear it from your care team, the best next step is to ask them what it means for your specific situation. Your healthcare providers can explain how this drug fits into your treatment and what to expect.

Next Steps for Patients and Caregivers

If belinostat has been mentioned as a treatment option, talking with your doctor or nurse about how it might help you is important. They can provide details about the benefits, risks, and how it fits with other treatments. You can also ask about clinical trials if you are interested in learning about new research involving this drug. Being informed helps you take an active role in your care and make decisions that feel right for you.